
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Guillain-barre Syndrome Market**

According to Intelli, the U.S. Guillain-barre Syndrome Market size was valued at USD 268.52 Million in 2024 and is projected to reach USD 386.55 Million by 2032, growing at a CAGR of 5.08% from 2025 to 2032.



Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening autoimmune neurological disorder in which the body’s immune system mistakenly attacks the peripheral nervous system, the network of nerves located outside of the brain and spinal cord. Guillain-Barré Syndrome typically manifests abruptly and advances quickly, often triggered by a preceding viral or bacterial infection. Common antecedents include *Campylobacter jejuni*, influenza, and, more recently, emerging pathogens such as the Zika virus and SARS-CoV-2. The hallmark symptoms of GBS include sudden muscle weakness and sensory disturbances such as numbness or tingling. In more severe cases, the condition can progress to full paralysis, including respiratory muscle involvement, requiring intensive medical intervention and, in some instances, mechanical ventilation. Initial symptoms of Guillain-Barré Syndrome often begin with tingling or prickling sensations in the lower limbs, particularly the legs and feet. These symptoms typically ascend through the body, a characteristic pattern known as *ascending paralysis*. If not promptly diagnosed and treated, the condition can deteriorate rapidly over the course of days to weeks, leading to significant motor impairment, disruptions in autonomic functions, and, in approximately 30% of cases, respiratory failure requiring mechanical ventilation.The impact of GBS extends beyond clinical challenges, influencing healthcare resource allocation, patient quality of life, and long-term rehabilitation planning. As the medical and scientific communities deepen their understanding of autoimmune neuropathies, Guillain-Barré Syndrome remains a focal point for innovation in neuroimmunology, personalized medicine, and biotechnology development particularly in the context of infectious disease surveillance and post-infection care.

**U.S. Guillain-barre Syndrome Market Definition**

**​**The U.S. Guillain-Barré Syndrome market encompasses the spectrum of medical products and services dedicated to the diagnosis, treatment, and management of Guillain-Barré Syndrome. This market includes therapeutic interventions such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange (Plasmapheresis), diagnostic tools like A close-up of hands holding a tablet and a pen

Description automatically generatedlumbar puncture, electromyography (EMG), and nerve conduction studies, as well as supportive care services. The U.S. Guillain-Barré Syndrome market is characterized by a focus on rapid diagnosis and effective treatment to mitigate disease progression and improve patient outcomes.

**U.S. Guillain-barre Syndrome Market Overview**

The U.S. Guillain-Barré Syndrome market is being propelled by several key drivers that collectively contribute to its sustained growth. A primary factor is the increasing incidence of GBS. Another critical driver of market growth is the advancement in therapeutic interventions, notably the increasing use of IVIG and Plasma Exchange. These treatments have demonstrated high efficacy in managing the acute stages of Guillain-Barré Syndrome and significantly contribute to faster and more complete patient recovery. Parallel to therapeutic progress, innovations in diagnostic methodologies such as lumbar puncture, EMG, and nerve conduction studies have greatly improved the accuracy and speed of diagnosis. These tools enable earlier intervention, which is essential for improving clinical outcomes and reducing long-term complications. Lastly, greater awareness among healthcare providers and patients has led to quicker referrals and earlier intervention, further supporting market expansion. These combined drivers are creating a dynamic and responsive market landscape for Guillain-Barré Syndrome care in the United States.

**U.S. Guillain-barre Syndrome Market Segmentation**

The market is segmented across several key dimensions including therapeutic type, diagnostic method, and distribution channel.

**U.S. Guillain-barre Syndrome Market, By Therapeutic Type**

* **IVIG**
* **Plasma Exchange**
* **Others**

In the U.S. Guillain-Barré Syndrome market, IVIG holds the largest share among therapeutic options. Plasma Exchange, the second major therapeutic segment, is witnessing steady growth and is increasingly used in patients who do not respond to IVIG or present with contraindications. The "Others" category includes supportive therapies and emerging treatments under clinical research, which currently represent a smaller portion of the market but are gaining attention as part of a more comprehensive, long-term care A close-up of hands holding a tablet and a pen

Description automatically generatedstrategy. Together, these therapeutic segments form the backbone of the U.S. Guillain-Barré Syndrome treatment landscape, reflecting both current clinical preferences and future potential for innovation.

**U.S. Guillain-barre Syndrome Market, By Diagnostic Method**

* **Lumbar Puncture**
* **Electromyography**
* **Nerve Conduction Studies**

In the U.S. Guillain-Barré Syndrome market, lumbar puncture dominates the diagnostic segment, accounting for approximately 45-50% of the market share. Electromyography (EMG) follows as the second most utilized diagnostic tool, contributing to about 30-35% of the market share. EMG is essential for assessing nerve function and detecting early signs of nerve damage in GBS patients. Nerve conduction studies, which make up around 25% of the market share, are frequently used in conjunction with EMG to evaluate the speed and efficiency of nerve signals, further aiding in the diagnosis and severity assessment of GBS.

**U.S. Guillain-barre Syndrome Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

In the U.S. Guillain-Barré Syndrome market, hospital pharmacies dominate the distribution landscape. This is due to the acute nature of GBS, which necessitates immediate treatment in hospital settings, including therapies like IVIG and Plasma Exchange. Retail pharmacies hold a smaller share, providing medications for follow-up care, such as pain management or long-term rehabilitation, once patients are discharged from the hospital. Lastly, online pharmacies represent an emerging segment. These digital platforms offer convenience and accessibility, particularly for ongoing treatment or supplemental medications, and are growing in importance as patients seek alternative, more accessible ways to manage their care.

**Key Players**

The “U.S. Guillain-Barré Syndrome market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market AbbVie, AstraZeneca, A close-up of hands holding a tablet and a pen

Description automatically generatedBaxter International, Biogen, Bristol-Myers Squibb, Cardinal Health, CSL Behring, Eli Lilly and Co., GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Teva Pharmaceuticals, Xenon Pharmaceuticals, Amgen among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Development**

* In 2024, ANX005 has received Orphan Drug Designation from the FDA, recognizing its potential to provide significant benefits over current treatments for Guillain-Barré Syndrome.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Guillain-Barré Syndrome market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Guillain-Barré Syndrome market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. GUILLAIN-BARRÉ SYNDROME MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. GUILLAIN-BARRÉ SYNDROME MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. GUILLAIN-BARRÉ SYNDROME MARKET, BY THERAPEUTIC TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 IVIG

5.3 Plasma Exchange

5.4 Others

**6 U.S. GUILLAIN-BARRÉ SYNDROME MARKET, BY DIAGNOSTIC METHOD**

6.1 Overview

6.2 Lumbar Puncture

6.3 Electromyography

6.4 Nerve Conduction Studies

**7 U.S. GUILLAIN-BARRÉ SYNDROME MARKET, BY DISTRIBUTION CHANNEL**

7.1 Overview

7.2 Hospital Pharmacies

7.3 Retail Pharmacies

7.4 Online Pharmacies

1. **U.S. GUILLAIN-BARRÉ SYNDROME MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 AbbVie**

* + 1. Overview
    2. A close-up of hands holding a tablet and a pen

       Description automatically generatedFinancial Performance
    3. roduct Outlook
    4. Key developments
  1. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Baxter International**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Biogen**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Cardinal Health**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  6. **CSL Behring**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Eli Lilly and Co.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **GlaxoSmithKline**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Medtronic**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  4. **Merck & Co.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Novartis**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Pfizer**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Regeneron Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Sanofi**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  9. **Teva Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **Xenon Pharmaceuticals**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **Amgen**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research